Found 1263 clinical trials
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536) …
- 16800 views
- 22 Aug, 2022
- 7 locations
Sickle Cell Disease Research Study - Fulcrum Therapeutics
The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.
- 12948 views
- 14 Sep, 2022
- 5 locations
A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo. For this, the impact of CSJ117 on disease symptom burden and lung function will be explored.
- 6 views
- 17 Sep, 2022
- 28 locations
A Study of CC-99677 in Participants With Active Ankylosing Spondylitis (AS SpA axSpA)
assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.
- 22 views
- 09 Jul, 2022
- 59 locations
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy (RESET-HA)
a 12-week period (Part I) that is followed by a year-long (52 week) open-label extension (Part II) to further evaluate the safety and maintenance of efficacy of TRM-201.
- 1 views
- 22 Sep, 2022
- 18 locations
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sjögren's Syndrome (pSjS) (phaethuSA)
period. The total duration of the study will be 24 weeks (28 weeks including maximum screening duration) for each participant, including a 12-week treatment period and a 12-week follow-up
- 123 views
- 09 Sep, 2022
- 39 locations
Opportunities Beyond the Narrative: An Intervention for Justice-Involved Youth
-experimental design to evaluate an innovative teen pregnancy prevention program, Project With, for incarcerated and other justice-involved youth in Southern California. Project With is a 12-lesson literary
- 26 views
- 12 May, 2022
- 1 location
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
> Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an
- 4 views
- 16 Sep, 2022
- 123 locations
A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines
with moderate to severe GL. This is a 12 week study in which eligible subjects will be enrolled into the study containing 2 treatment periods, double-blind period and open-label period
- 10 views
- 23 Sep, 2022
- 27 locations
A Randomized, Multi-Center, Double Blinded, Self-Initiated, Single Treatment Study Comparing Sitavig® (Acyclovir) 50 mg Muco-adhesive Buccal Tablet to Placebo in the Treatment of Herpes Labialis in Immunocompetent Adults
> There will be a 2 week treatment phase and a 12 month follow up phase. The participants in this study will not be required to visit the study site. Instead, the participants will have virtual meetings
- 0 views
- 19 Sep, 2022
- 1 location